Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
0.6900
-0.1140 (-14.18%)
At close: Mar 18, 2026, 4:00 PM EDT
0.7500
+0.0600 (8.70%)
After-hours: Mar 18, 2026, 7:39 PM EDT
Genenta Science Employees
Genenta Science had 13 employees as of December 31, 2024. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$785,995
Market Cap
13.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | -1 | -7.14% |
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Serina Therapeutics | 13 |
| Cocrystal Pharma | 11 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| AEON Biopharma | 5 |
| Cadrenal Therapeutics | 4 |
| Acurx Pharmaceuticals | 4 |
GNTA News
- 5 days ago - Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University - GlobeNewsWire
- 19 days ago - Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform - GlobeNewsWire
- 7 weeks ago - Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments - Benzinga
- 7 weeks ago - Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator - GlobeNewsWire
- 3 months ago - Genenta Science Provides Update on CEO Ownership - GlobeNewsWire
- 4 months ago - Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewsWire
- 5 months ago - Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating - Seeking Alpha
- 5 months ago - Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire